Navigation Links
Abbott Introduces Molecular Diagnostic System Intended for Broad Identification of Infectious Agents
Date:7/21/2009

CHICAGO, July 21 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today unveiled its new PLEX-ID system currently in development for detecting and characterizing a wide range of pathogens, including infectious agents commonly transmitted in hospitals and other clinical sites. PLEX-ID is the next generation of Abbott's Ibis T5000(TM) Biosensor System and is among an innovative portfolio of instruments and tests the company is featuring this week at the American Association for Clinical Chemistry's 2009 Clinical Lab Expo.

"Research reported in several scientific venues has shown that the Ibis technology could offer applications for the rapid detection of a broad range of microbes, including bacteria, viruses and fungi, in a variety of specimens," said David Ecker, Ph.D., divisional vice president, research and development, Abbott Molecular.

Currently intended to be for research use only, PLEX-ID is a high-throughput technology that simultaneously enables identification and recognition of emerging organisms using a unique combination of both PCR (polymerase chain reaction) and mass spectrometry analysis for detection of microbes.

The system is designed to address a significant unmet clinical need by providing results in six to seven hours instead of three or more days as is required with culturing methods.

"The Ibis technology has demonstrated broad utility in a variety of research applications, including biodefense, forensics, epidemiology and infectious disease surveillance for public health applications," said Stafford O'Kelly, head of Abbott's molecular diagnostics business. "We believe the technology has the potential to be a powerful and versatile tool, particularly for the identification of hospital-borne pathogens."

The PLEX-ID is expected to receive CE Mark (Conformite Europeenne) for marketing in the European Union later this year.

Initial assays in development include bacteria-candida-antibiotic resistance (BCA), influenza and broad viral detection.

In an early research study, viral isolates from adenovirus, alphavirus, enterovirus, flavivirus, herpes virus and human parvovirus B19 were injected into human plasma specimens from healthy volunteers. This was followed by a retrospective study of 54 blinded samples of cerebral spinal fluid, urine and plasma. The Ibis technology detected all viral pathogens that were added to the plasma specimens with a limit of detection ranging from 15 to 125 copies. In the retrospective study, the system demonstrated 98 percent concordance with the reference method.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available at the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott Launches New Instrument to Complete Family of ARCHITECT Immunochemistry Analyzers
2. Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009
3. Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal(R) Vet, a New Chemotherapeutic Agent for Dogs
4. Abbott Hosts Conference Call for Second-Quarter Earnings
5. Abbott Receives CE Mark for Companys Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
6. Schmidt & Clark, LLP: FDA Reports Show Abbott Labs Subsidiary Failed to Disclose Parasite Eye Infections Tied to Contact Lens Solution
7. Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
8. Abbott Declares 342nd Consecutive Quarterly Dividend
9. Abbott Announces Launch of Next-Generation Embolic Protection System
10. Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging
11. Abbotts TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... KICKICO , a protocol built on ... to solve many catastrophic issues within funding campaigns. KICKICO developers are testing the platform, ... crowdfunding - the raising of funds through the power of many - has been ...
(Date:6/25/2017)... (PRWEB) , ... June 25, 2017 , ... FCPX LUT ... into an old-fashioned vintage look. FCPX LUT Vintage Volume 2 contains 60 different color-grade ... grain for distorted looks, vignettes and blurs to single out subjects, plus much more. ...
(Date:6/25/2017)... , ... June 25, 2017 , ... Republicans in the ... and replace Obamacare, called the Better Care Reconciliation Act. It differs significantly from the ... will need to be reconciled in committee, or the House will have to take ...
(Date:6/25/2017)... (PRWEB) , ... June 25, 2017 , ... CareSet Labs ... in New Orleans. This is a new, greatly improved version of the Doctor ... Act (FOIA) requests by Fred Trotter and subsequently called the the “Doctor Referral Dataset” ...
(Date:6/25/2017)... ... 25, 2017 , ... June is Men’s Health Month and the focus is on ... men in the U.S. and the third most common cause of cancer related death today; ... in seven will be diagnosed with prostate cancer during his lifetime. Those at highest ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... , June 7, 2017 Endo International plc ... 7, 2017, the Hon. Joseph R. Goodwin , ... West Virginia , entered a case ... Pelvic Repair System Products Liability Litigation (the "MDL") that ... cases to provide expert disclosures on specific causation within ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... TEL AVIV, Israel , May 30, 2017 /PRNewswire/ ... clinical stage pharmaceutical Company specializing in the development ... management will present a company overview at three ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: